Rüschoff J - Search Results

1

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.

Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G. Rüschoff J, et al. Virchows Arch. 2022 Nov;481(5):685-694. doi: 10.1007/s00428-022-03378-5. Epub 2022 Aug 16. Virchows Arch. 2022. PMID: 35970977 Free PMC article.

2

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J. Stoss OC, et al. Among authors: ruschoff j. Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25. Mod Pathol. 2015. PMID: 26403781 Free article. Clinical Trial.

3

[ISH-based HER2 diagnostics].

Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2020 Nov;41(6):606-613. doi: 10.1007/s00292-020-00841-5. Pathologe. 2020. PMID: 33001242 Review. German.

4

ISH-based HER2 diagnostics.

Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2021 Nov;42(Suppl 1):62-68. doi: 10.1007/s00292-020-00878-6. Epub 2020 Dec 21. Pathologe. 2021. PMID: 33346874 Review. English.

5

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH. Rüschoff J, et al. Virchows Arch. 2010 Sep;457(3):299-307. doi: 10.1007/s00428-010-0952-2. Epub 2010 Jul 28. Virchows Arch. 2010. PMID: 20665045 Free PMC article.

6

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH. Rüschoff J, et al. Pathologe. 2010 May;31(3):208-17. doi: 10.1007/s00292-010-1278-1. Pathologe. 2010. PMID: 20443098 German.

7

[New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis].

Denkert C, Lebeau A, Schildhaus HU, Jackisch C, Rüschoff J. Denkert C, et al. Among authors: ruschoff j. Pathologie (Heidelb). 2022 Nov;43(6):457-466. doi: 10.1007/s00292-022-01124-x. Epub 2022 Oct 13. Pathologie (Heidelb). 2022. PMID: 36227345 Free PMC article. Review. German.

8

Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Scheel AH, Penault-Llorca F, Hanna W, Baretton G, Middel P, Burchhardt J, Hofmann M, Jasani B, Rüschoff J. Scheel AH, et al. Among authors: ruschoff j. Diagn Pathol. 2018 Mar 12;13(1):19. doi: 10.1186/s13000-018-0696-x. Diagn Pathol. 2018. PMID: 29530054 Free PMC article.

9

[ErbB2 diagnostics in breast cancer--an update].

Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. Rüschoff J, et al. Pathologe. 2009 Mar;30(2):147-55. doi: 10.1007/s00292-009-1126-3. Pathologe. 2009. PMID: 19214513 German.

10

HER2 testing in gastric cancer: a practical approach.

Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. Rüschoff J, et al. Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6. Mod Pathol. 2012. PMID: 22222640 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

340 results

Search Page